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Abstract
Introduction Spinal cord injury (SCI) is caused by two
related but mechanistically distinct events: the primary
injury to the spinal cord is caused by a mechanic trauma;
the secondary injury is a cascade of cellular and molecular
events that exacerbates the initial damage.
Materials and Methods Neuroinflammation, an important
event in the secondary injury cascade, is critical in the
clearance of cellular debris after SCI. However, leukocytes
and microglia, recruited to the injury site during neuro-
inflammation, can exacerbate the initial damage following
SCI by secreting reactive oxygen species, matrix-
metalloproteinase, and proinflammatory cytokines. There-
fore, attenuating the activity of leukocytes and microglia is
an attractive therapeutic strategy to reduce the neurological
deficit associated with SCI.
Discussion In this regard, immunoglobulin G (IgG) is a
potential treatment candidate. IgG has been used clinically
to treat autoimmune disease and has been demonstrated to
attenuate the activities of leukocytes and microglia. In this
review, we discuss the potential use of IgG for SCI based
on the current understanding of the immune-modulating
mechanism of IgG and the role of neuroinflammation in
SCI.
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Pathobiology of Spinal Cord Injury
According to the Christopher and Dana Reeve Foundation,
there are over 1.2 million people living with spinal cord
injury (SCI) in the United States alone [1]. Approximately
12,000 new cases in the USA are reported each year, and
the average medical cost for a patient with SCI can be up to
$10 million. Aside from the financial burden, people with
SCI and their families and caregivers also deal daily with
the physical, emotional, and social effects of this devastat-
ing condition. Few treatments are currently available or are
even being investigated in clinical trials that address
neurological impairment following traumatic SCI [2].
Therefore, there is a dire need for effective treatments that
can reduce neurological deficit and improve a patient’s
quality of life following SCI.
SCI is caused by two mechanistically and chronologi-
cally distinct events: the primary injury is caused by a
mechanical force such as contusion, compression, or
laceration, and the secondary injury is a cascade of cellular
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The secondary injury cascade includes the disruption of
vasculature and the permeability of the blood-spinal cord
barrier, edema, ionic toxicity, inflammation, cell deaths
(necrosis and apoptosis), demyelination, and axonal degen-
eration (for a more extensive discussion, see [4]). While
neural cells at the injury epicenter die quickly due to the
primary injury, the cells in the surrounding regions of the
epicenter are lost in a delayed fashion. The end result of
the primary and secondary injury events is the substantial
loss of neurons and oligodendrocytes, cavitation, and the
formation of a glial scar that limits regeneration. Most
research in the field has been focused on understanding the
pathophysiology of the secondary damage and reducing the
amount of delayed cell loss following SCI.
Role of Inflammation in SCI
Cellular and Molecular Response Following SCI
Inflammation, a key event in the secondary injury cascade,
occurs immediately and persists for several weeks or
months following SCI. The inflammatory response is
critical for the clearance of cellular debris, which can
prevent the regeneration of surviving neurons. However,
overactivation of the inflammatory response can damage
healthy tissue and exacerbate the damage, which can lead to
poor functional recovery following SCI (for a more
extensive discussion, see [4, 5]). Microglia are recruited to
the injury site almost immediately. These cells secrete
proinflammatory cytokines, including interleukin (IL)-1β,
interleukin-6, and tumor necrosis factor-α (TNF-α), all of
which increase the extent of inflammation.
The maintenance of proinflammatory cytokine expres-
sion is then accomplished by immune reactive cells, which
are recruited to the injury epicenter. Endothelial cells
upregulate their cellular adhesion molecules (CAMs) in
response to the increased cytokines concentration, allowing
leukocytes to adhere to the wall of endothelial cells and
infiltrate the injury epicenter. The presence of neutrophils at
the injury site peaks at 24 h, and they are cleared within
48 h. The presence of monocytes and lymphocytes is not
observed at the injury site until 3 to 7 days after SCI.
Recruited Leukocytes and Microglia can Exacerbate SCI
Blood-borne leukocytes and central nervous system (CNS)
resident microglia/macrophages are recruited to the injury
epicenter as part of the inflammatory response. These cells
are essential in the clearance of cellular debris and in the
promotion of cellular regeneration by the secreting of
trophic factors and anti-inflammatory cytokines. However,
in the acute phase of SCI, immune reactive cells can
damage healthy tissues by releasing proinflammatory
cytokines, reactive oxygen species (ROS), and matrix-
metalloproteinase (MMPs, Fig. 1). Neutrophils can further
increase the extent of the inflammatory response by
producing proinflammatory mediators such as TNF-α, IL-
1, and IL-8 [6]. MMP-9 and MMP-2 produced by
neutrophils, macrophages, and endothelial cells can further
break down the blood-brain barrier and increase leukocyte
infiltration [7]. The influx of neutrophils and hematogenous
macrophages, together with microglia, is a major source of
ROS and inducible nitrous oxide synthase [8, 9]. These
events can cause an increase in reactive oxygen radicals and
nitrous oxide (NO) at the injury epicenter. Reactive oxygen
radicals can react with NO to produce peroxynitrite
(ONOO
−) following injury [10]. The magnitude of the
secondary damage can increase due to oxidation and
nitrosylation of proteins, DNA, and lipids by reactive
oxygen radicals and ONOO
−. In addition, activated macro-
phages can physically induce axonal retraction and impede
axonal regeneration [11].
Inflammation Following SCI: A Double-Edged Sword
Despite intensive research, the role of the inflammatory
response in SCI is not fully understood. Many studies
suggest both anti-inflammatory and proinflammatory
treatments in SCI promote favorable outcomes. Anti-
inflammatory treatments, such as the depletion of macro-
phages [12], the inhibition of MMP-9 [13], the reduction in
the availability of CAMs [14], and the inhibition of
neutrophil infiltration [15], are beneficial for recovery after
SCI in animals and humans. The transplantation of macro-
phages into the injury site has been demonstrated to be
beneficial to the recovery from SCI. In addition, wild-type
mice were demonstrated to recover from SCI better than
immune-deficient mice [16, 17]. Despite these studies,
more research is needed to better understand the in-
flammatory process of spinal injury and to elucidate the
exact benefits of proinflammatory and anti-inflammatory
treatments.
Proposed Immunomodulating Mechanism
of Intravenous Immunoglobulin G
Immunoglobulin G (IgG) isolated from pooled human
serum has been used clinically to treat many autoimmune
neuropathies such as Guillain–Barré syndrome. However,
the mechanism underlying the observed benefits from
intravenous IgG treatment is unclear. Many immunomodu-
lating mechanisms for IgG have been proposed, and the
exact one could potentially be a combination of many
S110 J Clin Immunol (2010) 30 (Suppl 1):S109–S112mechanisms. IgG preparations have been demonstrated to
contain agonist anti-Fas antibodies, which induce monocyte
and lymphocyte apoptosis via a caspase-dependent pathway
[18]. IgG preparations also contain autoantibodies toward
the sialic acid-binding immunoglobulin-like lectin-9 that
can induce neutrophil apoptosis via caspase-dependent
pathways and pathways dependent on ROS [19]. In
addition, IgG has been demonstrated to inhibit the
production of MMP-9 in cultured macrophages via its Fc
and F(ab´)2 fragments [20]. IgG also has been demonstrated
to bind neutrophil chemotactic factors C3a and C5a at low
affinity via the constant region of the F(ab´)2 fragment [21].
C5a is a potent chemotactic factor for neutrophil and
macrophage recruitment and activation [22]. Recently, it
has been suggested that the IgG immunomodulating
mechanism is achieved through the regulation of the
expression levels of Fcγ receptors FcγRIIIA and FcγRIIB.
[23] These receptors have low affinity for the Fc domain of
the IgG molecules, and they are coexpressed on the surface
of neutrophils, macrophages, mast cells, B-lymphocytes,
and natural killer cells (for a detailed review, see [23]).
These Fcγ receptors work antagonistically to maintain a
constant balance between stimulatory and inhibitory signals
in the immune system. The upregulation of the activating
FcγRIIIA receptor has been linked to immune-complex
diseases and autoimmune disorders, including Arthus
reaction, rheumatoid arthritis, glomerulonephritis, systemic
lupus erythematosus, and immune thrombocytopenic pur-
pura [23]. Specifically, the sialylated N-linked glycan on
the Fc fragment of IgG is required for the Fc fragment to
bind to the SIGN-R1 (mice)/DC-SIGN (human) receptor on
regulatory macrophages, which then upregulate the expres-
sion of immune inhibitory FcγRIIB receptors on effector
macrophages [24]. The sialic acid residue is part of a
glycan, which is linked to the Fc fragment at the asparagine
at position 297.
IgG: A Potential Neuroprotective Treatment for SCI
IgG has been shown to modulate the immune response by
inducing apoptosis in leukocytes, neutralizing components
of the complement system, and inhibiting the activation of
leukocytes. Therefore, using IgG to attenuate the detrimen-
tal effects of the inflammatory response in the acute phase
of SCI is an attractive therapeutic strategy to reduce the
neurological deficit associated with SCI and to improve
patients’ functional recovery. IgG has been shown to reduce
neurological deficit associated with CNS injury such as
traumatic brain injury and stroke, both of which have
Fig. 1 Potential interactions of IgG with the neuroinflammatory
response following SCI. Schematic diagram represents how the
infiltration of microglia and leukocytes could exacerbate the initial
damage. Microglia and leukocytes are recruited to the injury epicenter
where they produce neurotoxic substances that cause neuronal and
oligodendrocytic cell death in the secondary injury cascade. IgG has
the potential to reduce the extent of secondary damage by interacting
with microglia and leukocytes in the following mechanism: (1) inhibit
microglia activation and reduce proinflammatory cytokine production,
(2) inhibit leukocyte recruitment to the injury epicenter following SCI
by acting on endothelial cells, and (3) inhibit leukocyte activation by
upregulation of the inhibitory FcγIIB receptor. BBB blood-brain
barrier, LIF leukemia inhibitory factor, ROS reactive oxygen species,
NOS nitrous oxide synthase, MMPs matrix-metalloproteinases
J Clin Immunol (2010) 30 (Suppl 1):S109–S112 S111similar pathobiology to SCI. To date, only one study
presenting preliminary data on the use of IgG for SCI has
been reported [25]. Therefore, extensive characterization of
the potential neuroprotective property of IgG at the
molecular, cellular, and behavioral level is required before
moving IgG into clinical testing for SCI. Unpublished
preliminary findings from our laboratory show that IgG
treatment reduces secondary damage and improves hind-
limb function following SCI in rats. This evidence provides
a strong rationale to investigate the potential neuroprotec-
tive properties of IgG in greater detail and to fully elucidate
the underlying mechanism for SCI.
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